Conditions: Healthy Alzheimer's Disease Mild Cognitive Impairment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 50
Healthy volunteers: yes

Brief summary:
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's Disease (AD), and those with mild-to-moderate AD. The study will measure how much LY2599666 gets into the bloodstream and how long it takes the body to get rid of it. It will also evaluate how LY2599666 affects the body. The study has three parts. Part A will last about 2 months. Parts B and C will each last about 23 weeks. Participants may only enroll in one part.

Detailed description:

Arms:
arm 1: LY2599666 given subcutaneously (SC) once. arm 2: Placebo matching LY2599666 given SC once. arm 3: LY2599666 given SC once weekly for 12 weeks (13 doses). arm 4: Placebo given SC once weekly for 12 weeks (13 doses). arm 5: Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks. arm 6: Placebo given IV once weekly or once every 4 weeks for 12 weeks.

Interventions: intervention 1: LY2599666 intervention 2: Solanezumab intervention 3: Placebo SC intervention 4: Placebo IV
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered IV intervention 3: Administered SC intervention 4: Administered IV

Protocol document: